INTRODUCTION {#s1}
============

Bladder cancer is the ninth most common malignancy worldwide \[[@R1]\]. It has been estimated about 80000 newly diagnosed bladder cancer cases in the United States in 2015 \[[@R2]\]. Bladder Urothelial Carcinoma (BLCA) is the most common histological subtype of bladder cancer. Overall, about 70% of bladder tumors are non-muscle-invasive bladder cancer, and the others are muscle-invasive bladder cancer \[[@R3]\]. Despite recent advances in the surgical technique, the overall survival of BLCA patients has not been dramatically improved, and the five-year survival rate remains at only 50-60% \[[@R4]--[@R6]\]. Therefore, it is necessary to identify novel independent biomarkers for diagnostic and prognosis and to develop new targeted therapies for BLCA patients.

Long non-coding RNAs (lncRNAs) are an important category of non-coding RNAs (ncRNAs) with little or no protein-coding capacity, which range from 200 nucleotides to multiple kilobases in length \[[@R7], [@R8]\]. Accumulated evidence suggests that lncRNAs play crucial roles in regulating gene expression at transcriptional, posttranscriptional and epigenetic levels \[[@R7], [@R9]\], and participate in various biological processes and pathways, such as transcriptional regulation, cell growth and tumorigenesis \[[@R10], [@R11]\]. Like mRNA and miRNA, some well-studied lncRNAs have been found to play critical oncogenic or tumor suppressive roles in various types of cancers \[[@R12]--[@R14]\]. For instance, *HOTAIR*, *MALAT1* and *CRNDE* have been showed as oncogenic roles \[[@R15]--[@R25]\], while *GAS5*, *MEG3* and *lincRNA-p21* as tumor suppressive roles \[[@R26]--[@R32]\]. Currently, several expression-based lncRNA signatures have been identified in glioblastoma \[[@R33]\], oesophageal squamous cell carcinoma \[[@R34]\], breast cancer \[[@R35]\], colorectal cancer \[[@R36]\], non-small cell lung cancer \[[@R37]\], multiple myeloma \[[@R38]\] and ovarian cancer \[[@R39]\], highlighting their potential roles as novel independent biomarkers for cancer prognosis. For bladder cancer, recent studies have also revealed that lncRNAs (*HOTAIR*, *SPRY4-IT1*, *SUMO1P3* and *PANDAR*) are aberrantly expressed in BLCA patients \[[@R40]--[@R43]\]. However, the prognostic power of expression-based lncRNA signature for predicting BLCA patients' survival remains unclear.

In this work, we performed a comprehensive analysis for lncRNA expression profiles and corresponding clinical information of BLCA patients in the TCGA training dataset. We identified four lncRNAs significantly associated with patients' survival and constructed a four-lncRNA signature that can effectively predict patients' survival. The testing dataset and entire dataset further validated the prognostic power of the four-lncRNA signature. Our results demonstrated the four-lncRNA signature can function as novel independent biomarkers for BLCA prognosis and provide novel insights into understanding of the underlying molecular mechanism of BLCA.

RESULTS {#s2}
=======

Identification of prognostic lncRNAs associated with patients' survival from the training dataset {#s2_1}
-------------------------------------------------------------------------------------------------

The 234 patients with BLCA were randomly divided into a training dataset (*n* = 117) and a testing dataset (*n* = 117). The training dataset was analyzed to identify prognostic lncRNAs. At first, we performed a univariate Cox regression analysis to evaluate the association between the expression profiles of each lncRNA and patients' survival in the training dataset. The result showed that four lncRNAs were identified as prognostic lncRNAs (*p-value* \< 0.001). The detailed information of these four lncRNAs was showed in Table [1](#T1){ref-type="table"}. Among these prognostic lncRNAs, the lncRNAs (*AC005682.5* and *CTD-2231H16.1*) with higher expression profiles were associated with shorter survival (coefficient \> 0), while the remaining two lncRNAs (*CTB-92J24.2* and *RP11-727F15.13*) with higher expression profiles were associated with longer survival (coefficient \< 0).

###### The detailed information of four prognostic lncRNAs significantly associated with overall survival in patients with BLCA

  Ensembl ID        Gene symbol        Chromosomal position               *P* value^a^   Hazardratio^a^   Coefficient^b^
  ----------------- ------------------ ---------------------------------- -------------- ---------------- ----------------
  ENSG00000228649   *AC005682.5*       chr7: 22,854,178-22,861,579 (+)    3.39E-04       1.613            0.371
  ENSG00000249430   *CTD-2231H16.1*    chr5: 92,151-139,863 (+)           8.44E-04       0.175            0.175
  ENSG00000269397   *CTB-92J24.2*      chr19: 23,927,788-23,929,287 (+)   2.22E-04       0.609            -0.251
  ENSG00000269463   *RP11-727F15.13*   chr11: 62,807,682-62,808,063 (-)   6.88E-04       0.736            -0.232

^a,b^Derived from the univariate and multivariate Cox regression analyses in 117 patients of the training dataset.

Construction and validation of a four-lncRNA signature for predicting patients' survival in the training dataset {#s2_2}
----------------------------------------------------------------------------------------------------------------

To construct a prognostic signature, these four lncRNAs were analyzed using a multivariate Cox regression analysis in the training dataset with survival as the dependent variable and other clinical information as covariables. Then we constructed a prognostic signature by integrating the expression profiles of the four lncRNAs and corresponding estimated regression coefficient derived from above multivariate Cox regression analysis as follows: Risk score = (0.371 × expression value of *AC005682.5*) + (0.175 × expression value of *CTD-2231H16*.1) + (-0.251 × expression value of *CTB-92J24.2*) + (-0.232 × expression value of *RP11-727F15.13*). With the four-lncRNA signature, we calculated a risk score for each patient in the training dataset and ranked them according to increased risk score. Thus, 117 patients of the training dataset were classified into a high-risk group (*n* = 59) and a low-risk group (*n* = 58) using the median risk score (-1.12) as the cutoff point. The Kaplan-Meier analysis showed a significant difference in patients' survival between the high-risk group and the low-risk group (log-rank test *p-value* = 8.94E-09; Figure [1A](#F1){ref-type="fig"}). Patients in the high-risk group had significantly shorter survival (median 5.60 months) than those in the low-risk group (median 7.52 months). To evaluate how well the four-lncRNA signature for predicting the 5-year survival, the time-dependent ROC curve analysis was carried out. The AUC for the four-lncRNA signature was 0.807 at the survival of five years (Figure [1B](#F1){ref-type="fig"}), demonstrating the competitive performance of the four-lncRNA signature for survival prediction in the training dataset. In the univariate Cox regression analysis of the training dataset, the four-lncRNA risk score were significantly associated with patients' survival (*p-value* = 3.33E-05, HR = 23.141, 95% CI = 5.248-102.043; Table [2](#T2){ref-type="table"}).

![The four-lncRNA signature in prognosis of overall survival of BLCA patients in the training dataset\
**A**. The Kaplan-Meier curves of overall survival between high-risk and low-risk patients in the training dataset. **B**. The ROC curve for survival prediction by the four-lncRNA signature within five years as the defining point in the training dataset. **C**. The four-lncRNA risk score distribution, overall survival of patients and heatmap of the four-lncRNA expression profiles in the training dataset.](oncotarget-08-10485-g001){#F1}

###### Univariate and multivariate Cox regression analyses in each dataset

  Variables                     Univariate analysis   Multivariate analysis                                              
  ----------------------------- --------------------- ----------------------- ---------- --------------- --------------- ----------
  Training dataset (n=117)                                                                                               
   Four-lncRNA risk score                                                                                                
    Low risk/High risk          23.141                5.248-102.043           3.33E-05   21.761          4.637-102.129   9.44E-05
   Age                                                                                                                   
    ≤65/\>65                    1.072                 0.444-2.591             0.876      0.700           0.237-2.071     0.520
   Gender                                                                                                                
    Female/Male                 0.786                 0.304-2.031             0.620      0.909           0.331-2.498     0.853
   Subtype                                                                                                               
    Non-Papillary/Papillary     0.343                 0.100-1.173             8.82E-02   0.290           0.060-1.401     0.123
   Stage                                                                                                                 
    II                          1 (reference)                                            1 (reference)                   
    III                         2.408                 0.598-9.701             0.217      0.246           0.031-1.946     0.184
    IV                          3.350                 0.944-11.882            6.13E-02   1.369           0.335-5.591     0.662
  **Testing dataset (n=117)**                                                                                            
   Four-lncRNA risk score                                                                                                
    Low risk/High risk          2.365                 1.042-5.372             3.97E-02   2.459           1.067-5.666     3.46E-02
   Age                                                                                                                   
    ≤65/\>65                    1.148                 0.479-2.754             0.756      1.333           0.549-3.240     0.525
   Gender                                                                                                                
    Female/Male                 1.199                 0.481-2.991             0.697      1.229           0.488-3.096     0.662
   Subtype                                                                                                               
    Non-Papillary/Papillary     0.507                 0.175-1.473             0.212      0.633           0.213-1.885     0.411
   Stage                                                                                                                 
    II                          1 (reference)                                            1 (reference)                   
    III                         1.680                 0.515-5.484             0.390      1.479           0.422-5.180     0.541
    IV                          2.472                 0.791-7.720             0.119      2.024           0.634-6.468     0.234
  **Entire dataset (n=234)**                                                                                             
   Four-lncRNA risk score                                                                                                
    Low risk/High risk          5.581                 2.839-10.972            6.18E-07   4.975           2.527-9.795     3.45E-06
   Age                                                                                                                   
    ≤65/\>65                    1.118                 0.603-2.073             0.722      1.202           0.643-2.248     0.564
   Gender                                                                                                                
    Female/Male                 0.994                 0.516-1.915             0.985      1.145           0.587-2.233     0.691
   Subtype                                                                                                               
    Non-Papillary/Papillary     0.433                 0.194-0.967             4.12E-02   0.553           0.242-1.268     0.162
   Stage                                                                                                                 
    II                          1 (reference)                                            1 (reference)                   
    III                         2.070                 0.840-5.099             0.114      1.070           0.383-2.992     0.898
    IV                          2.917                 1.256-6.775             1.28E-02   1.866           0.774-4.497     0.165

The distribution of the risk score, overall survival and prognostic lncRNA expression profiles in 117 patients of the training dataset were showed in Figure [1C](#F1){ref-type="fig"}, ranked according to increased risk score. Patients with high-risk scores had higher mortality than patients with low-risk scores. For patients with high risk scores, the expression profiles of lncRNAs (*AC005682.5* and *CTD-2231H16.1*) are significantly up-regulated, while the remaining two lncRNAs (*CTB-92J24.2* and *RP11-727F15.13*) were down-regulated.

Validation of the four-lncRNA signature for survival prediction in the testing dataset and entire dataset {#s2_3}
---------------------------------------------------------------------------------------------------------

To validate the prognostic power of the four-lncRNA signature for survival prediction, 117 patients of the testing dataset were divided into a high-risk group (*n* = 62) and a low-risk group (*n* = 55) with the same lncRNA signature and cutoff point derived from the training dataset. In consistent with the findings in the training dataset, the result showed that a significantly different survival between the high-risk group and the low-risk group (log-rank test *p-value* = 3.49E-02, median 6.62 months *vs*. 6.97 months; Figure [2A](#F2){ref-type="fig"}). The AUC for the four-lncRNA signature was 0.656 at the survival of five years in the testing dataset. In the univariate Cox regression analysis of the testing dataset, the four-lncRNA risk score were significantly associated with patients' survival (*p-value* = 3.97E-02, HR = 2.365, 95% CI = 1.042-5.372; Table [2](#T2){ref-type="table"}).

![The Kaplan-Meier curves of overall survival between high-risk and low-risk patients in the testing and entire dataset\
**A**. The Kaplan-Meier curves for the testing dataset. **B**. The Kaplan-Meier curves for the entire dataset.](oncotarget-08-10485-g002){#F2}

When the four-lncRNA signature was further applied to the entire TCGA dataset, similar results were observed. As in the training and testing dataset, the four-lncRNA signature could also classify 234 patients of the entire dataset into a high-risk group (*n* = 121) and a low-risk group (*n =* 113) with significantly different survival (log-rank test *p-value* = 3.89E-08, median 6.43 months *vs*. 7.33 months; Figure [2B](#F2){ref-type="fig"}). In the entire dataset, the AUC for the four-lncRNA signature was 0.758 at the survival of five years. The univariate Cox regression analysis also demonstrated that the four-lncRNA risk score was significantly associated with patients' survival in the entire dataset (*p-value* = 6.18E-07, HR = 5.58, 95% CI = 2.84-10.97; Table [2](#T2){ref-type="table"}). Taken together, the above results demonstrated good reliability and reproducibility of the four-lncRNA signature for predicting BLCA patients' survival.

Independence of the four-lncRNA signature for survival prediction from other clinical variables {#s2_4}
-----------------------------------------------------------------------------------------------

To evaluate whether the prognostic power of the four-lncRNA signature was independent of other clinical variables including age, gender, subtype and tumor stage, the multivariate Cox regression analyses were first carried out in each dataset. The results from the three datasets demonstrated that the four-lncRNA risk score was significantly associated with patients' survival. Specifically, the four-lncRNA signature still maintained an independent association with survival after adjustment for other clinical variables in the training dataset (*p-value* = 9.44E-05, HR = 21.761, 95% CI = 4.637-102.129), testing dataset (*p-value* = 3.46E-02, HR = 2.459, 95% CI = 1.067-5.666) and entire dataset (*p-value* = 3.45E-06, HR = 4.975, 95% CI = 2.527-9.795; Table [2](#T2){ref-type="table"}). Next, stratified analyses were then performed according to age, tumor stage and subtype, respectively. First, all 234 BLCA patients were stratified by the age (65 years old) into a younger dataset (*n* = 86) and an elder dataset (*n* = 148). The four-lncRNA signature could classify the younger dataset into a high-risk group (*n* = 45) and a low-risk group (*n* = 41) with significantly different survival (log-rank test *p-value* = 1.64E-04, median 6.00 months *vs*. 6.77 months; Figure [3A](#F3){ref-type="fig"}). Similarly, the four-lncRNA signature was also able to classify the elder dataset into a high-risk group (*n* = 76) and a low-risk group (*n* = 72) with significantly different survival (log-rank test *p-value* = 1.02E-04, median 6.45 months *vs*. 7.60 months; Figure [3B](#F3){ref-type="fig"}). Then all patients were further stratified by the tumor stage into an early dataset (stage II and stage III, *n* = 156) and a late dataset (stage IV, *n* = 78). Similar prognostic power of the four-lncRNA signature was significant in both the early dataset and late dataset. Patients in the early dataset were classified into a high-risk group (*n* = 80) with shorter survival and a low-risk group (*n* = 76) with longer survival (log-rank test *p-value* = 2.25E-04, median 6.48 months *vs*. 7.05 months; Figure [3C](#F3){ref-type="fig"}). Similar results were observed in the late dataset (log-rank test *p* = 1.55E-05, median 5.93 months *vs*. 7.73 months; Figure [3D](#F3){ref-type="fig"}). Finally, all patients were stratified by the subtype into a non-papillary dataset (*n* = 165) and a papillary dataset (*n* = 69). Significant differences in patients' survival between the high-risk groups and the low-risk groups were also observed in the two datasets (log-rank test *p-value* = 5.52E-05, median 6.50 months *vs*. 7.13 months, Figure [3E](#F3){ref-type="fig"}; log-rank test *p-value* = 4.33E-04, median 3.73 months *vs*. 7.47 months, Figure [3F](#F3){ref-type="fig"}). The results of multivariate Cox regression analyses, together with the stratified analyses, demonstrated that the prognostic power of the four-lncRNA signature was independent of other clinical variables for survival prediction of patients with BLCA.

![Survival analyses of all BLCA patients stratified by age, stage, tumor subtype with the four-lncRNA signature\
**A**. The Kaplan-Meier curves for the younger dataset (age ≤ 65, n = 86). **B**. The Kaplan-Meier curves for the elder dataset (age \> 65, n = 148). **C**. The Kaplan-Meier curves for the early dataset (stage II/III, n = 156). **D**. The Kaplan-Meier curves for the late dataset (stage IV, n = 78). **E**. The Kaplan-Meier curves for the non-papillary dataset (subtype of non-papillary, n = 165). **F**. The Kaplan-Meier curves for papillary dataset (subtype of papillary, n = 69).](oncotarget-08-10485-g003){#F3}

Functional characteristics of the four prognostic lncRNAs {#s2_5}
---------------------------------------------------------

To investigate potential functional roles of the four prognostic lncRNAs in BLCA tumorigenesis, we carried out functional enrichment analyses to predict their functions \[[@R44]\]. We first calculate Spearman correlation coefficients between lncRNAs and protein-coding genes by examining the paired lncRNA and the protein-coding gene expression profiles of 234 patients with BLCA. A total of 1405 protein-coding genes were significantly correlated with at least one of four prognostic lncRNAs (Spearman correlation coefficient \> 0.40). Functional enrichment analyses of GO and KEGG pathways revealed that 1405 protein-coding genes were significantly enriched in 50 GO terms (a *p-value* of \< 0.05 and an enrichment score of \> 1.0) and 7 KEGG pathways (a *p-value* of \< 0.05 and a fold enrichment of \> 2.0). These functionally related GO terms were mainly organized into seven functional clusters including assembly and disassembly of protein and macromolecules, transcription, signal transduction and response to stimulus, cell apoptosis and death, metabolic and catabolic process, cell development, carbohydrate metabolic (Figure [4A](#F4){ref-type="fig"}). Seven significantly enriched KEGG pathways were observed including tight junction, aldosterone-regulated sodium reabsorption, pathogenic escherichia coli infection, adherens junction, valine, leucine and isoleucine degradation, p53 signaling pathway, glycosphingolipid biosynthesis (Figure [4B](#F4){ref-type="fig"}). These results of the functional enrichment analyses suggested that the four prognostic lncRNAs may participate in tumorigenesis through regulating or interacting protein-coding genes to affect known BLCA-related biological processes and pathways.

![Functional enrichment analyses of the protein-coding genes co-expressed with the four prognostic lncRNAs\
**A**. The functional enrichment map of GO terms. *Each node* represents a GO term. An *edge* represents the overlap of the shared genes between connecting terms. *Node size* represents the number of gene in the GO terms. *Color intensity* is proportional to enrichment significance. **B.** Significantly enriched KEGG pathway.](oncotarget-08-10485-g004){#F4}

DISCUSSION {#s3}
==========

Considerable efforts have been made during the past years to identify expression-based prognostic biomarkers for bladder cancer at protein-coding genes and miRNAs levels \[[@R45]--[@R47]\]. More recently, accumulated evidence indicates that dysregulated lncRNAs are implicated in various tumorigenesis processes including proliferation, invasion and apoptosis by acting as tumor oncogenes or suppressor, which has developed a new area for biomarkers. Additionally, plenty of aberrant lncRNA expression in multiple cancers was discovered by the transcriptional profiling analyses \[[@R48], [@R49]\], highlighting their potential roles as novel independent biomarkers for cancer prognosis. By now, several expression-based lncRNA signatures have been identified in glioblastoma, oesophageal squamous cell carcinoma, breast cancer, colorectal cancer, non-small cell lung cancer, multiple myeloma and ovarian cancer. Compared with protein-coding genes, lncRNAs exhibit greater tissue-, disease- and developmental stage-specific expression, and their expression is more closely related to the tumor status and biological functions \[[@R50]--[@R54]\]. Indeed, several lncRNAs, such as *HOTAIR*, *SPRY4-IT1*, *SUMO1P3* and *PANDAR* have been found to be associated with bladder prognosis \[[@R40], [@R43]\]. However, to date, the prognostic power of expression-based lncRNA signature for predicting survival in patients with BLCA has not yet been investigated.

Here, we performed a comprehensive analysis for lncRNA expression profiles and corresponding clinical information of BLCA patients in the training dataset, and identified four lncRNAs significantly associated with patients' survival and constructed a four-lncRNA signature that can effectively predict survival of BLCA patients. Further ROC curve analysis demonstrated the competitive performance of the four-lncRNA signature for predicting 5-year survival in the training dataset. Then the prognostic power of the four-lncRNA signature was validated in an independent non-overlapping dataset and an entire dataset, demonstrated good reliability and reproducibility of the four-lncRNA signature for predicting BLCA patients' survival. Next, we performed multivariate Cox regression analyses in each dataset to evaluate whether the prognostic power of the four-lncRNA signature was independently of other clinical variables, including age, gender, subtype and tumor stage. The four-lncRNA signature was demonstrated to still maintain an independent association with patients' survival after adjustment for other clinical variables. In the stratified analyses, the four-lncRNA signature showed prognostic power for the younger dataset (age ≤ 65) and the elder dataset (age \> 65), in which patients belonging to the two datasets could be classified into high-risk and low-risk groups with significant differences in patients' survival. Similar prognostic power of the four-lncRNA signature was also significant in the early dataset (stage II and stage III) and the late dataset (stage IV), in which patients in the two datasets were able to classified into high-risk and low-risk groups with significantly different survival. Moreover, similar results were observed in the non-papillary dataset and the papillary dataset. Taken together, these results demonstrated that the prognostic power of the four-lncRNA signature was independent of other clinical variables for survival prediction of patients with BLCA.

Up to date, although more than tens of thousands of lncRNAs have been discovered in humans over the past few decades \[[@R55]\], only a handful of lncRNAs were functionally well-characterized and the functional study of lncRNAs remains in its infancy. Previous studies have suggested that lncRNAs participated in biological processes and pathways by regulating or interacting with protein-coding genes involved in the same processes, making it possible to infer lncRNA biological functions from their co-expressed protein-coding genes \[[@R44], [@R56], [@R57]\]. To detect the biological implication of the four prognostic lncRNAs in BLCA, we performed GO and KEGG functional enrichment analyses for co-expressed protein-coding genes. The results indicated the important functional roles of the four prognostic lncRNAs in tumorigenesis.

In summary, by performing a comprehensive analysis for lncRNA expression profiles and corresponding clinical information, our study identified four prognostic lncRNAs were significantly associated with BLCA patients' survival and constructed a four-lncRNA signature that can effectively predict patients' survival. The prognostic power of the four-lncRNA signature was independent of other clinical variables, and showed superior performance compared to known traditional clinical variables in a way. Our results demonstrated the four-lncRNA signature can function as novel independent biomarkers for BLCA prognosis and provided novel insights into understanding the underlying molecular mechanism of BLCA.

MATERIALS AND METHODS {#s4}
=====================

BLCA datasets and patient information {#s4_1}
-------------------------------------

The lncRNA expression profiles and corresponding clinical information of BLCA patients were obtained from [T]{.ul}he [C]{.ul}ancer [G]{.ul}enome [A]{.ul}tlas (TCGA) data portal (up to May 27, 2016; <https://gdc-portal.nci.nih.gov/>). A total of 234 patients were enrolled in this study after removal of patients without available clinical information. Clinical information of BLCA patients used in this study, including age, gender, subtype and stage. More detailed clinical characteristics of all 234 BLCA patients in this study were listed in Table [3](#T3){ref-type="table"}.

###### Clinical characteristics of patients with BLCA in this study

  Characteristics   Training dataset(n=117)   Testing dataset(n=117)   Entire dataset(n=234)
  ----------------- ------------------------- ------------------------ -----------------------
  Vital status                                                         
   Alive            96 (82.1%)                91 (77.8%)               187 (79.9%)
   Dead             21 (17.9%)                26 (22.2%)               47 (20.1%)
  Age                                                                  
   ≤65              50 (42.7%)                36 (30.8%)               86 (36.8%)
   \>65             67 (57.3%)                81 (69.2%)               148 (63.2%)
  Gender                                                               
   Female           31 (26.5%)                28 (23.9%)               59 (25.2%)
   Male             86 (73.5%)                89 (76.1%)               175 (74.8%)
  Subtype                                                              
   Non-papillary    82 (70.1%)                83 (70.9%)               165 (70.5%)
   Papillary        35 (29.9%)                34 (29.1%)               69 (29.5%)
  Stage                                                                
   II               41 (35.0%)                29 (24.8%)               70 (29.9%)
   III              37 (31.6%)                49 (41.9%)               86 (36.8%)
   IV               39 (33.3%)                39 (33.3%)               78 (33.3%)

Acquisition of lncRNA expression profiles {#s4_2}
-----------------------------------------

The lncRNAs derived from TCGA and lncRNAs from GENCODE project \[[@R58]\] were cross-reference by Ensemble ID to reduce redundant. Then the lncRNA expression profiles were defined as those with an average RPKM ≥ 0.3 across all 234 BLCA patients. Finally, we obtained expression profiles of 12730 lncRNAs in 234 BLCA patients.

Construction of a prognostic lncRNA signature {#s4_3}
---------------------------------------------

The lncRNAs expression profiles were normalized by log2 transformed. The association between the expression profiles of each lncRNA and patients' survival was evaluated in the training dataset using a univariate Cox regression analysis with survival as the dependent variable. LncRNAs whose expression profiles were significantly associated with patients' survival were identified (*p-value* \< 0.001) as prognostic lncRNAs, and then subjected to a multivariate Cox regression analysis in the training dataset with survival as the dependent variable and other clinical information as covariables. Subsequently, a prognostic lncRNA signature was constructed based on a linear combination of the expression profiles of prognostic lncRNAs with weighted by the estimated regression coefficient as follows: $$\textit{Risk Score}(RS) = {\sum\limits_{i = 1}^{N}{\,(\textit{Exp}_{i}*\textit{Coe}_{i})}}$$

where *N* is the number of prognostic lncRNAs, *Exp~i~* is the expression profiles of *lncRNA~i~*, and *Coe~i~* is the estimated regression coefficient of *lncRNA~i~* derived from the multivariate Cox regression analysis. The lncRNA signature could calculate a risk score for each patient. With the lncRNA signature, BLCA patients in each dataset were classified into high-risk and low-risk groups using the median risk score derived from the training dataset as a cutoff point.

Statistical analysis {#s4_4}
--------------------

Differences in patients' survival between the high-risk group and the low-risk group in each dataset were accessed by the Kaplan-Meier survival analyses, and compared by the two-sided log-rank test using the R package "survival" \[[@R59]\]. Furthermore, in order to evaluate whether the prognostic power of the four-lncRNA signature was independent of other clinical variables including age, gender, subtype and tumor stage, multivariate Cox regression and stratified analyses were carried out in each dataset with survival as the dependent variable, lncRNA risk score and other clinical variables as explanatory variables. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. The time-dependent receiver operating characteristic (ROC) curve analyses within five years as the defining points were performed using the R package "survivalROCR" \[[@R60]\], which has been widely used to evaluate the prognostic performance for survival prediction \[[@R61]\]. Area under the ROC curve (AUC) values were calculated from the ROC curves. All analyses were performed using R software and Bioconductor (version 3.3.0).

Functional enrichment analyses {#s4_5}
------------------------------

Spearman correlation coefficients were computed to evaluate co-expression relationships between prognostic lncRNAs and protein-coding genes. Functional enrichment analyses for the co-expressed protein-coding genes were carried out using the DAVID Bioinformatics Tool (version 6.7) \[[@R62], [@R63]\] limited to Gene ontology (GO) terms in the "Biological Process" (GOTERM-BP-FAT) and Kyoto encyclopedia of genes and genomes (KEGG) pathway categories with the human whole genome as the background. GO terms with a *p-value* of \< 0.05 and an enrichment score of \> 1.0, KEGG pathway with a *p-value* of \< 0.05 and a fold enrichment of \> 2.0 were considered as significantly enriched function annotations. Significant enrichment results were visualized and clustered based on the similar function using the Enrichment Map plugin \[[@R64]\] in Cytoscape (version 3.4.0) \[[@R65]\] and R package "goProfiles" \[[@R66]\].

This work is supported by National Natural Science of China to Dong Dong (Grant No. is 31200956).

**CONFLICTS OF INTEREST**

The authors declare that they have no competing interest.

**Authors' contributions**

DD conceived and designed the experiments. ZB, ZW and DD analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.
